See more : Scancell Holdings plc (SCLP.L) Income Statement Analysis – Financial Results
Complete financial analysis of PetVivo Holdings, Inc. (PETV) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of PetVivo Holdings, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
- ChemoMetec A/S (CHEMM.CO) Income Statement Analysis – Financial Results
- Tuesday Morning Corporation (TUEM) Income Statement Analysis – Financial Results
- Krung Thai Bank Public Company Limited (KTB.BK) Income Statement Analysis – Financial Results
- Essentra plc (ESNT.L) Income Statement Analysis – Financial Results
- ReoStar Energy Corp. (REOS) Income Statement Analysis – Financial Results
PetVivo Holdings, Inc. (PETV)
About PetVivo Holdings, Inc.
PetVivo Holdings, Inc., a biomedical device company, engages in the manufacturing, commercializing, and licensing of medical devices and biomaterials for the treatment of afflictions and diseases in animals. Its lead product is Spryng, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses. The company's pipeline products also include 17 therapeutic devices for veterinary and human clinical applications. PetVivo Holdings, Inc. was founded in 2009 and is headquartered in Minneapolis, Minnesota.
Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 968.71K | 917.16K | 115.59K | 12.58K | 3.59K | 77.94K | 1.51K | 7.12K | 75.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost of Revenue | 229.18K | 526.82K | 201.15K | 10.70K | 19.71K | 77.94K | 643.39K | 746.85K | 743.63K | 1.20M | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 739.53K | 390.35K | -85.57K | 1.88K | -16.12K | 0.00 | -641.88K | -739.72K | -668.63K | -1.20M | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit Ratio | 76.34% | 42.56% | -74.03% | 14.97% | -449.33% | 0.00% | -42,508.48% | -10,383.51% | -891.51% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Research & Development | 1.27M | 690.58K | 474.88K | 98.23K | 12.67K | 200.98K | 118.94K | 167.89K | 168.60K | 4.40K | 119.30K | 0.00 | 0.00 | 157.30K |
General & Administrative | 6.69M | 5.02M | 3.15M | 1.77M | 1.23M | 3.60M | 2.17M | 16.23M | 3.16M | 1.20M | 36.85M | 82.40K | 102.40K | 103.68K |
Selling & Marketing | 3.40M | 3.41M | 1.35M | 94.98K | 171.51K | 38.35K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.80K |
SG&A | 10.09M | 8.43M | 4.50M | 1.86M | 1.40M | 3.64M | 2.17M | 16.23M | 3.16M | 1.20M | 36.85M | 82.40K | 102.40K | 105.48K |
Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 559.54K | 646.92K | 2.17M | 16.23M | 3.16M | 0.00 | 24.44M | 0.00 | 0.00 | 0.00 |
Operating Expenses | 11.36M | 9.12M | 4.97M | 1.96M | 1.97M | 4.49M | 2.29M | 16.40M | 3.33M | 1.20M | 36.97M | 82.40K | 102.40K | 262.78K |
Cost & Expenses | 11.59M | 9.65M | 5.17M | 1.97M | 1.99M | 4.57M | 2.29M | 16.40M | 3.33M | 1.20M | 36.97M | 82.40K | 102.40K | 262.78K |
Interest Income | 0.00 | 15.84K | 9.85K | 228.60K | 32.19K | 84.95K | 0.00 | 0.00 | 0.00 | 0.00 | 19.53K | 0.00 | 0.00 | 0.00 |
Interest Expense | 0.00 | 0.00 | 0.00 | 228.60K | 32.19K | 84.95K | 74.02K | 188.51K | 270.58K | 399.16K | 0.00 | 0.00 | 0.00 | 0.00 |
Depreciation & Amortization | 126.85K | 114.43K | 65.15K | 86.71K | 559.54K | 646.92K | 643.39K | 746.85K | 743.63K | 10.48K | 36.97M | 3.81K | 227.00 | 659.00 |
EBITDA | -10.49M | -8.62M | -4.99M | -1.87M | -1.49M | -3.92M | -1.64M | -16.39M | -2.51M | -1.20M | -19.68K | -78.59K | -102.18K | -262.12K |
EBITDA Ratio | -1,083.35% | -952.23% | -4,345.73% | -14,885.32% | -39,724.53% | -5,032.45% | -108,737.02% | -219,579.00% | -3,343.40% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Operating Income | -10.62M | -8.73M | -5.06M | -1.96M | -2.02M | -4.67M | -2.29M | -16.39M | -3.25M | -1.20M | -36.97M | -82.40K | -102.40K | -262.78K |
Operating Income Ratio | -1,096.45% | -952.23% | -4,374.69% | -15,574.72% | -56,190.97% | -5,995.70% | -151,345.50% | -230,062.51% | -4,334.91% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Total Other Income/Expenses | -333.96K | 15.84K | 41.53K | -1.56M | -66.60K | -84.95K | -52.02K | -132.05K | -1.48M | -363.84K | -19.68K | -3.81K | -227.00 | -659.00 |
Income Before Tax | -10.96M | -8.72M | -5.01M | -3.52M | -2.08M | -4.76M | -2.34M | -16.52M | -4.73M | -1.57M | -36.99M | -86.21K | -102.63K | -263.44K |
Income Before Tax Ratio | -1,130.92% | -950.50% | -4,338.76% | -28,007.47% | -58,047.21% | -6,104.70% | -154,790.60% | -231,916.03% | -6,307.73% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Income Tax Expense | 0.00 | -15.84K | -73.21K | 228.60K | 32.19K | 84.95K | 74.02K | -990.17K | -1.08M | 388.68K | -19.68K | 0.00 | 0.00 | 0.00 |
Net Income | -10.96M | -8.70M | -4.94M | -3.75M | -2.11M | -4.76M | -2.34M | -15.53M | -3.65M | -1.57M | -36.99M | -86.21K | -102.63K | -263.44K |
Net Income Ratio | -1,130.92% | -948.77% | -4,275.42% | -29,824.89% | -58,944.23% | -6,104.70% | -154,790.60% | -218,017.03% | -4,868.99% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
EPS | -0.78 | -0.85 | -0.56 | -0.61 | -0.10 | -1.03 | -0.61 | -7.71 | -2.07 | -0.91 | -308.77 | -1.55 | -2.00 | -5.86 |
EPS Diluted | -0.78 | -0.85 | -0.56 | -0.61 | -0.10 | -1.03 | -0.61 | -7.71 | -2.07 | -0.91 | -308.77 | -1.55 | -2.00 | -5.86 |
Weighted Avg Shares Out | 13.97M | 10.22M | 8.76M | 6.20M | 21.22M | 4.61M | 3.81M | 2.01M | 1.77M | 1.71M | 119.81K | 55.69K | 51.37K | 44.98K |
Weighted Avg Shares Out (Dil) | 13.97M | 10.22M | 8.76M | 6.20M | 21.22M | 4.61M | 3.81M | 2.01M | 1.77M | 1.71M | 119.81K | 55.69K | 51.37K | 44.98K |
PetVivo Holdings to Present at Emerging Growth Conference on September 29, 2021
Josh Wilhelm Joins PetVivo Holdings, Inc. as the Director of Manufacturing
These Reddit Penny Stocks Exploded Today, Are They On Your List?
PetVivo Holdings, Inc. to Exhibit at Western Veterinary Conference in Las Vegas, Nevada
PetVivo Changes Brand Name of Signature Osteoarthritis Product to “SPRYNG”
Russell Siakel Joins PetVivo Holdings, Inc. as the Director of Marketing
PetVivo Holdings to Present at Emerging Growth Conference on August 18, 2021
PetVivo Holdings Announces Closing of Public Offering and Nasdaq Listing
Source: https://incomestatements.info
Category: Stock Reports